MedPath

NATIONAL INSTITUTES OF HEALTH

NATIONAL INSTITUTES OF HEALTH logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Subsidiary, Private
Established
1948-01-01
Employees
1K
Market Cap
-
Website
http://www.nidcr.nih.gov
Clinical Trials
Related News

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

Phase 2
Terminated
Conditions
Recurrent Thymoma and Thymic Carcinoma
Stage IVA Thymoma
Invasive Thymoma and Thymic Carcinoma
Stage III Thymoma
Stage IVB Thymoma
Interventions
First Posted Date
2008-07-21
Last Posted Date
2015-06-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
21
Registration Number
NCT00718809
Locations
πŸ‡ΊπŸ‡Έ

Stanford University Hospitals and Clinics, Stanford, California, United States

πŸ‡ΊπŸ‡Έ

Indiana University Medical Center, Indianapolis, Indiana, United States

Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C

Phase 1
Completed
Conditions
Hepatitis C, Chronic
First Posted Date
2008-07-18
Last Posted Date
2019-12-17
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
81
Registration Number
NCT00718172
Locations
πŸ‡ΊπŸ‡Έ

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Oral Nifedipine to Treat Iron Overload

Phase 1
Completed
Conditions
Iron Overload
Thalassemia
Hemochromatosis
First Posted Date
2008-07-10
Last Posted Date
2017-07-02
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
6
Registration Number
NCT00712738
Locations
πŸ‡ΊπŸ‡Έ

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Phase 2
Terminated
Conditions
Melanoma
Interventions
Biological: ALVAC-MART-1 vaccine
Biological: Aldesleukin
Biological: incomplete Freund's adjuvant
Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
First Posted Date
2008-06-30
Last Posted Date
2015-10-28
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
50
Registration Number
NCT00706992
Locations
πŸ‡ΊπŸ‡Έ

National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, United States

Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)

Phase 3
Completed
Conditions
Healthy Volunteers
Interventions
Procedure: Fat Meal
Procedure: Carb meal
Drug: Placebo
First Posted Date
2008-06-27
Last Posted Date
2020-07-22
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
31
Registration Number
NCT00706381
Locations
πŸ‡ΊπŸ‡Έ

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

T-Cell Project: Epidemiologic Component

Completed
Conditions
Peripheral T-Cell Lymphoma
First Posted Date
2008-06-26
Last Posted Date
2017-07-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
800
Registration Number
NCT00705809
Locations
πŸ‡ΊπŸ‡Έ

National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, United States

Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Secondary Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia
Interventions
Other: pharmacological study
Other: laboratory biomarker analysis
First Posted Date
2008-06-23
Last Posted Date
2014-11-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
19
Registration Number
NCT00703300
Locations
πŸ‡ΊπŸ‡Έ

Ohio State University Medical Center, Columbus, Ohio, United States

Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

Phase 2
Completed
Conditions
Recurrent Mantle Cell Lymphoma
Recurrent Non-Hodgkin Lymphoma
Interventions
Other: Laboratory Biomarker Analysis
First Posted Date
2008-06-23
Last Posted Date
2018-08-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
65
Registration Number
NCT00703664
Locations
πŸ‡ΊπŸ‡Έ

Moffitt Cancer Center, Tampa, Florida, United States

πŸ‡ΊπŸ‡Έ

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

πŸ‡ΊπŸ‡Έ

Northwestern University, Chicago, Illinois, United States

and more 9 locations

Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease

Phase 2
Completed
Conditions
Imatinib Mesylate
Sclerotic Graft Versus Host Disease
Interventions
Drug: Gleevec, STI571(Imatinib Mesylate)
First Posted Date
2008-06-20
Last Posted Date
2020-03-30
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
20
Registration Number
NCT00702689
Locations
πŸ‡ΊπŸ‡Έ

National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, United States

A New Method for Determining Gastric Acid Output Using a Wireless Capsule

Completed
Conditions
Gastric Acid Secretory Disorders
Interventions
Device: Pentagastrin Injection BP
First Posted Date
2008-06-20
Last Posted Date
2025-06-29
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
80
Registration Number
NCT00702533
Locations
πŸ‡ΊπŸ‡Έ

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy